preservative-free
Sponsors
Ionis Pharmaceuticals Inc., Anaptysbio Inc., Anaptysbio Inc., Amgen Inc.
Conditions
Chemotherapy-induced Thrombocytopenia in Adult Subjects with GastrointestinalModerate to Severe Rheumatoid ArthritisPancreaticSevere Hypertriglyceridemia.Severe hypertryglyceridemiaTransthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)or Colorectal Cancer
Phase 2
Phase 3
ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
CompletedCTIS2022-501420-20-00
Start: 2023-05-17End: 2025-09-12Target: 248Updated: 2025-09-03
A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)
CompletedCTIS2023-507148-35-00
Start: 2019-10-03End: 2025-01-09Target: 60Updated: 2025-06-26
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
CompletedCTIS2024-510696-38-00
Start: 2022-03-08End: 2025-05-28Target: 368Updated: 2025-06-30
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Active, not recruitingCTIS2024-514434-20-00
Start: 2020-06-29Target: 413Updated: 2025-11-05